3DMed is seeking a highly motivated scientist to be a key contributor to our Investigational New Drug (IND) program. The successful candidate will join a diverse team charged with integrating chemical biology, functional genomics, and molecular profiling to elucidate mechanisms of action (MOA) and biomarker discovery for compounds originating from phenotypic screens and therapeutic area projects. He/she will work closely with extended team members, including biologists, medicinal chemists, data scientists, and the high throughput biology group. He/she will be a critical part of the design and execution of strategies (assays and data integration) to target validation, biomarker discover and drug development.

Qualifications:
-PhD in genomics sciences, cell or molecular biology
-3+ years additional experience relevant to cancer drug discovery.
-Demonstrated track record in target discovery and/or elucidation of compound MOA (publications, years of industrial or academic experience) is a strong requirement for this position.
-Strong background in genomic technologies and molecular profiling are required.
-Excellent oral and written communication skills and a track record of collaboration with medicinal chemists and data scientists are required
-Broad knowledge of the oncology field and a strong background in molecular cell biology
-Experience of drug discovery in liver cancer will be a plus

Key Leadership:
-New target identification and validation
-Cellular & in vivo assay development, evaluation of new technologies, and championing early stage drug discovery programs as lead biologist
-Be actively engaged in bench-based, hands-on research
-Provide direction, consulting, mentoring and training to Associate Scientists
-Present strategy and data in a variety of settings
-Create a learning environment, open to suggestions and experimentation for improvement.
-Embraces the ideas of others, nurtures innovation and manages innovation to reality.
-Work closely with scientists from other disciplines and the leadership team to make key decisions on compound and program progression

思路迪精准医疗集团（3DMed）于2010年成立，总部位于上海浦江高科技园区。秉承“做肿瘤精准医疗领域的创新型领导者”的愿景，思路迪从成立之初一直专注于肿瘤领域。目前已成为全国最大的肿瘤精准医疗全程管理和新药开发公司，形成肿瘤精准预防、精准治疗和精准药物开发三位一体的业务模式。通过多年的研发投入，建成全球最大的肝癌原代细胞库平台、二代测序平台和大数据平台。通过整合健康人基因组信息、患者肿瘤基因组信息和药物作用信息大数据，支持三大业务的发展。公司共获得14家国内知名风险投资机构累计4轮数亿元人民币资金的注入。
思路迪目前共有员工240余人，其中硕士、博士60多名。研发团队由来自美国哈佛大学、麻省理工学院、罗切斯特大学，国立卫生研究院和瑞士苏黎世大学等著名高校院所以及国际知名药厂的资深科学家成，平均拥有超过10年以上的肿瘤研究经验，积累4万多例肿瘤样本生物信息分析和大数据挖掘的经验。营销团队主要来自原班跨国制药公司，具有丰富的市场开拓和商业运营经验。我们与国内100多家三甲医院开展合作，300多名肿瘤医生构成的专家团队，为不同人群提供精准医疗服务。